Key Finding: Live biotherapeutic matches donor FMT in treating recurrent C. diff infection

GMJ
By
Prof. Giorgi Pkhakadze
0 Min Read
Medical illustration comparing manufactured biotherapeutic capsules to traditional fecal microbiota transplant procedure
Phase 1b trial shows manufactured 15-strain biotherapeutic achieves similar efficacy to traditional fecal transplant in treating recurrent C. difficile infection. Both treatments demonstrated 85-90% success rates. — Photo: National Institute of Allergy and Infectious Diseases / Pexels
1 min read|33 words

85-90% success rate: Both manufactured biotherapeutic MTC01 and traditional fecal transplant prevented recurrent C. difficile infection in phase 1b trial. Standardized therapy matches whole stool effectiveness.

Read the full article on GMJ Newsroom →

Was this article helpful?

Share This Article
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
NHS workforce planning faces strategic uncertainty as UK prioritises domestic medical graduates

NHS workforce planning faces uncertainty as new legislation prioritises UK medical graduates…

Maternal mortality crisis deepens for Sudanese refugee women in Central African Republic

Pregnant Sudanese refugee women in Central African Republic face 138 times higher…

Home Exercise Program Reduces Cognitive Decline During Cancer Chemotherapy

New trial shows home-based exercise significantly improved attention and reduced cognitive problems…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like